Monthly Archives: May 2023

Tom Dwan Wins Largest Pot in Live-Stream Poker History ($3.1 … – PokerNews.com

Posted: May 31, 2023 at 7:48 pm

The final day of the Hustler Casino Live $1 million buy-in game has produced some truly epic pots, but none more so than one Tom Dwan took down for $3,081,000 million the largest pot in live-stream poker history.

About six hours into Tuesday's stream, which had more than 50,000 concurrent viewers throughout much of the night, the best hand of them all took place. When the HCL Twitter page hyped it up as the hand that will "break the internet," they weren't spewing hyperbole.

Earlier in the show, "durrrr" won a massive pot against Doug Polk, whose failed bluff attempt on the river cost him a $1.1 million pot. In that hand, Dwan tank-called both the turn on the river with a monster hand, leading some to believe he slow-rolled his opponent. While that hand was quite entertaining, it pales in comparison to one Dwan played later in the session.

During the fourth and final $1 million game on Hustler Casino Live, there were some sick bluff attempts. Some got through, others didn't. One that did was a hand where "LSG Hank" wagered over $900,000 on the river with ace-high and forced Polk off pocket aces.

And then there was an attempted bluff that cost "Wes Side" Wesley, one of the HCL fan favorites, a California mansion. Wesley had bought in for $3 million, more than anyone else at the table. But he could only hold onto that stack for about five hours.

The stand up game was on during the record-breaking hand. For those unfamiliar with this gimmicky action game, the player who is last to win a hand must pay everyone else at the table a $6,000 fee. So, that adds an extra dynamic, which often baits players into playing more aggressive to avoid being the last to stand.

As for the hand itself, Wesley three-bet to $30,000 with AK and Polk folded after having seen Wesley's cards. During the hand, Polk was in an awkward position as he had to do his best to not give off any tells to either player in the hand.

Following the three-bet, Dwan then raised to $100,000 with QQ and his opponent five-bet to $275,000 and was called to see a flop of 388. Dwan would check-call a $125,000 bet and the pot was already over $800,000. The turn was the 5 and Wesley was still stuck on ace-high, but he fired out another massive wager, this time for $350,000, which put "durrrr" into a brief tank. He'd eventually call and then the 6 would appear on the river.

Knowing he could only win if he bet, Wesley put Dwan to the test for his remaining $786,000 stack. The former Full Tilt Poker pro again tanked as he faced a difficult decision for a seven-figure pot with nothing but one pair, albeit an over pair. After some thought, he made the gutsy call and took down a $3.1 million pot, the largest in live-stream poker history.

As for Wesley, he's built up a "tight" reputation on Hustler Casino Live. You can put that characterization to rest. He seemed to take the loss in stride.

With that hand, Dwan was up more than $2 million on the day at the time of publishing. The stream would continue on the Hustler Casino Live YouTube channel.

Read the original here:

Tom Dwan Wins Largest Pot in Live-Stream Poker History ($3.1 ... - PokerNews.com

Posted in History | Comments Off on Tom Dwan Wins Largest Pot in Live-Stream Poker History ($3.1 … – PokerNews.com

For Patients With Birthmarks, Psychosocial Interventions Improved … – Dermatology Times

Posted: at 7:48 pm

A psychosocial intervention and public exhibition improved the overall wellbeing and self image of individuals with birthmarks.

In a recent study,1 researchers sought to determine the impact of a public exhibition and professional photoshoot on the wellbeing of individuals with congenital melanocytic nevi (CMN). Furthermore, they sought to evaluate the exhibitions impact on the public perception of people with birthmarks. They cited a lack of existing studies examining the psychosocial aspects of having a birthmark, including the potential impact of therapeutic interventions.

Study authors described a patient recruitment effort led by Caring Matters Now, a United Kingdom-based charity supporting individuals with CMN, in 2016. Caring Matters Now partnered with a UK-based photographer to take patient portraits. Individuals with extensive and/or visible CMN were eligible for participation, and participation was not limited to geographic location, amassing participants from 5 continents. Prospective participants were required to meet with the photographer virtually and provide written consent.

Before and after photographing participants, researchers asked the 30 participants (or their parents, if under the age of 18) to complete a survey describing their photoshoot experience and behaviors pre and post photoshoot completion. The questionnaire asked participants whether the photoshoot made them feel:

They also asked participants whether they considered what they wore in relation to their CMN, their level of confidence in crowded places, and their level of confidence about showing their CMN.

All photos were publicly displayed in London, UK, for a 10-day duration in March 2019. Members of the public who visited the exhibition were asked to complete a survey; of the more than 8000 visitors, 464 agreed to complete the survey. The survey asked visitors whether the exhibition made them feel:

More than 90% of photoshoot and exhibition participants with CMN responded positively, agreeing or strongly agreeing, with all points of the questionnaire. Furthermore, responses from participants following the photoshoot and exhibition were positive and demonstratedsignificantly increased confidence. 33% of parents representing their older children described the experience as inspiring, while 57% of parents representing their young children described the experience as beautiful.

While only 51% of exhibition visitors described hearing of CMN prior to viewing the photos, more than 85% agreed or strongly agreed with all points of the questionnaire. 74% of attendees were individuals with CMN who described the exhibition as being very helpful in their appreciation and self-perception of their difference.

Study limitations, as noted by study authors, included the studys self-selective nature and a lack of collection of demographic data from exhibition visitors, aside from gender.

In the era of social media, where the negative psychological effects of posting self-photographs are frequently reported, the positive effect of this exhibition on the views of the general public is a perhaps surprising demonstration of the power of this novel approach. In particular, the general public not only looked more positively on the participants with visible difference, but felt better regarding their own appearance, study authors wrote. These data supportthe impression of the UK support group Caring Matters Now Charity, that non-hiding of visible difference on the skin can have beneficial psychological effects. Further studies will be required to assess whether this approach works in the context of other forms of visible difference, and whether the effects can be replicated using the exhibition book.

Reference

Read more here:
For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times

Posted in Psoriasis | Comments Off on For Patients With Birthmarks, Psychosocial Interventions Improved … – Dermatology Times

The history of spy animals; ‘Blue Ribbon Kitchen’ offers award … – NPR

Posted: at 7:48 pm

The history of spy animals; 'Blue Ribbon Kitchen' offers award-winning recipes : Here & Now Anytime Recycling plastic creates microplastics that contaminate the air and water, a new study found. Grist reporter Joseph Winters joins us to talk about what this means amid a pollution crisis. And, an alleged Russian spy has surfaced in the waters of Sweden. The spy, Hvaldimir, is a beluga whale. There is a long history of animals being used for espionage in military conflict, and Manchester Metropolitan University lecturer Gervase Phillips joins us to unpack it. Then, Linda Skeens won 25 ribbons at the Virginia-Kentucky district fair last summer. She's cataloged this impressive feat in a new book, "Blue Ribbon Kitchen." The cookbook details her award-winning recipes and offers some insight into her life in Appalachia.

Recycling plastic creates microplastics that contaminate the air and water, a new study found. Grist reporter Joseph Winters joins us to talk about what this means amid a pollution crisis.

And, an alleged Russian spy has surfaced in the waters of Sweden. The spy, Hvaldimir, is a beluga whale. There is a long history of animals being used for espionage in military conflict, and Manchester Metropolitan University lecturer Gervase Phillips joins us to unpack it.

Then, Linda Skeens won 25 ribbons at the Virginia-Kentucky district fair last summer. She's cataloged this impressive feat in a new book, "Blue Ribbon Kitchen." The cookbook details her award-winning recipes and offers some insight into her life in Appalachia.

Connect with us:

Find more stories from today's show here.

Follow us on Twitter, Facebook and Instagram.

Subscribe to our podcast here.

Email the show at letters@hereandnow.org

View post:

The history of spy animals; 'Blue Ribbon Kitchen' offers award ... - NPR

Posted in History | Comments Off on The history of spy animals; ‘Blue Ribbon Kitchen’ offers award … – NPR

LOOKING BACK: A Vicksburg home with Stamps on history – The … – Vicksburg Post

Posted: at 7:48 pm

Published 8:00 am Wednesday, May 31, 2023

By Nancy Bell, Vicksburg Foundation for Historic Preservation

The one-story, six-bay galleried house at 820 Grove St. was built prior to 1886 and at that time was the home of W.H. Auter, a special officer with the Y and MV Passenger Depot, and his son, W.H. Auter, who ran the lunch stand at the depot.

The house had two large additions at the rear and a stables. Shortly thereafter the house became a rental property. In May 1889, the house was listed for rent, advertised as a seven-room house with stables and a large yard, and newly painted and repaired.

In 1890, it was the home of P.W. Hilton and Capt. and Mrs. M.L. Dedman. The funeral of Betsie Hilton was in the home on Aug. 26 of that year. Advertisements in the paper stated that the house was for rent again in 1891 and 1893.

W.H. Auter, now the depot master, and his wife, Addie, were again living in the house in 1904 with relatives: H.V. Auter, a driver with American Express Company, and Richard O. Auter, a billing clerk with Southern Express Company.

By 1906, Meyer and Elka Cornblatt called the house, home. Living with them were their children Rosalie, David, Abraham, Leah and Mary. Rosalie was married to Charles Lustburg in the house on July 22, 1908, by Rabbi Nemtzov. Meyer owned a dry goods store on North Washington Street with both David and Abraham working as clerks there in 1906.

Abraham moved to Columbus, Miss. and died there of pneumonia on Aug. 24, 1922. His wife, Sarah, and small daughter, Evelyn, brought his body back to Vicksburg to be buried in the family plot in the Jewish Cemetery. The funeral took place in the house on Grove Street.

Elka died in 1924 and shortly thereafter Meyer moved and the house was listed as the home of Mrs. Ada Lewis, the widow of Silas Lewis.

By 1935, the house was vacant and was again rental property until Roberta Stamps bought it for her family, including her son, Vicksburg Fire Department Chief Derrick Stamps. The house continues to be loved and lived in by Mrs. Stamps.

More:

LOOKING BACK: A Vicksburg home with Stamps on history - The ... - Vicksburg Post

Posted in History | Comments Off on LOOKING BACK: A Vicksburg home with Stamps on history – The … – Vicksburg Post

Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable … – MD Magazine

Posted: at 7:48 pm

Robert Hariri, MD, PhD

Credit: Celularity

Stem cell pioneer Celularity (CELU) shared exciting results from a recent clinical trial investigating the efficacy of CYNK-001, the company's proprietary natural killer cell therapy.

The trial focused on treating patients with relapsed and refractory acute myeloid leukemia (AML) disease, who face low chances of a cure which has led to the development of a reliable gene manufacturing system that adheres to US Food and Drug Administration (FDA) regulations and produces substantial quantities of exceptional cellular products, according to CEO Robert Hariri, MD, PhD.

If you can utilize (these placenta cells) and identify the starting point for producing cell therapy products like T cells, natural killer cells, and even mesenchymal stem cells, it gives you a great deal of flexibility in your therapeutic development strategies, he explained.

The clinical trial demonstrated that treatment with CYNK-001 was well-tolerated by patients and exhibited no associated toxicities, even at the highest doses administered. Remarkably, the grafts showcased measurable graft-versus-leukemia effects without the need for high doses of chemotherapy commonly used in autologous transplants or the risk of graft-versus-host disease (GVHD) typically associated with standard allogeneic transplants.

Weve been grounded in a technology platform that is highly diversified and leverages the unique source material, the postpartum placenta, which we are credited with discovering over 20 years ago, as an ideal source of cells for the emerging therapeutic space, Hariri said in an interview.

Additionally, the companys manufacturing systems and the inclusion of all usable materials left in the organ for the development of cell therapy products are what sets Celularity aside.

"We want to basically combine the natural killer cells from the placenta, which are completely unmodifiedthese are nonengineered natural killer cellsso their natural anticancer activity is supported by lymphodepletion and administration of the supporting cytokine IL2 or IL15, gave us the answers we were looking at," Hariri said.

Read more from the original source:
Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine

Posted in Psoriasis | Comments Off on Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable … – MD Magazine

Nalbuphine ER Tablets Show Promise as Cough Therapy in … – MD Magazine

Posted: at 7:48 pm

Toby Maher, MD, PhD

Credit: Twitter

In a recent crossover trial, patients with idiopathic pulmonary fibrosis (IPF) showed reduced cough after treatment with nalbuphine extended-release tablets (NAL ER). The investigators, led by Toby Maher, MD, PhD, Keck School of Medicine, University of Southern California, stated there are currently no cough therapies approved for this population.1

Because IPF is a progressive lung disease that scars the lung tissue, the lung function of these patients is compromised and accompanied by respiratory symptoms, cough is one of the most common.

The study was a randomized, double-blind, placebo-controlled crossover trial that involved a pair of 22-day treatment periods, with a 2-week washout period in between. NAL ER was administered at an initial dose of 27 mg once daily, which was then titrated up to 162 mg twice daily by day 16.

Investigators assessed the percent change from baseline in hourly daytime objective cough frequency, as measured by an electronic cough monitor, for the primary endpoint of the study. Changes in objective 24-hour cough frequency, cough severity, and breathlessness, based on patient-reported outcomes were secondary endpoints.

The analysis included 41 patients with IPF who received at least one dose of study medication after being randomly assigned. During the NAL ER treatment period, the team observed a significant reduction in daytime objective cough frequency, with a 75.1% decrease compared with the placebo treatment period's reduction of 22.6%.

Investigators reported the finding corresponded to a 52.5 percentage point decrease from baseline (P < 0.001) at day 21, when adjusting for placebo effects. The therapy demonstrated a 76.1% decrease (95% CI, 83.1-69.1) in 24-hour objective cough frequency, while the placebo only showed a 25.3% decrease (43.9-6.7), resulting in a 50.8 percentage point placebo-adjusted change.

Common adverse events exhibited with the treatment included nausea, fatigue, constipation, and dizziness, which were more frequent compared with the placebo group and should be considered when evaluating the overall benefit-risk profile of NAL ER in this population, investigators said.

These safety results are similar to those of a trial of low-dose morphine in chronic cough that reported constipation and drowsiness in 40% and 25% of patients, respectively, the research stated.

Based on the short-term crossover trial results, the team suggested that NAL ER shows promise in reducing cough frequency for individuals with IPF. Given the lack of approved therapies targeting this clinical concern, the findings indicated significant development in the field, according to the study.

However, it was acknowledged that further research is needed to contribute to a better understanding of the treatment's overall efficacy, tolerability, and clinical utility in the management of cough in IPF patients.

Particularly, larger and longer trials evaluating the long-term efficacy and safety of the treatment as a cough therapy. Additionally, the impact of the treatment on cough severity and patient-reported outcomes should also be further explored.

Although our trial was not designed to statistically test other outcomes, the data are encouraging enough to merit further assessment in longer and larger clinical studies. Such trials permit weighing the long-term effects on cough against the adverse effects and loss of efficacy due to habituation associated with chronic opiate use, investigators wrote.

Visit link:
Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine

Posted in Psoriasis | Comments Off on Nalbuphine ER Tablets Show Promise as Cough Therapy in … – MD Magazine

The Oldest Olympic Champions In Swimming History – SwimSwam

Posted: at 7:48 pm

This will be a part of a series featuring analyzing Olympic medalists in swimming by age, thanks to the data compiled by SwimmingStats guruDaniel Takata(@Swimming Stats).

After we took a look at the youngest Olympic champions in swimming history earlier this month, its now time to analyze the opposite end of the spectrumthe oldest Olympic gold medalists in the sports history.

As we discovered in the earlier article, swimmers tend to peak in their early 20s, with women sometimes doing so in their late teens.

As a result of that, its incredibly rare to see a swimmer experience success at the highest level after their 30th birthday. There have been just 11 swimmers in history to win Olympic gold after their 30th birthday, and only five of them have done so in an individual event.

The oldest Olympic champ in history isAnthony Ervin, who stunningly returned to the top of the podium in the mens 50 freestyle in Rio (2016) 16 years after winning the same event in Sydney (2000) when he was. 19-year-old.

In fact, the seven oldest gold medalists have come in the last 20 years, due to legendary swimmers such as Dara Torres,Michael Phelps,Jason Lezak andRyan Lochte having wrapped up their careers relatively recently. American swimmers feature heavily on the list, with the strength of the U.S. relays (and funding keeping American swimmers in the sport longer than other nations in certain cases) a factor.

Torres is the oldest female Olympic gold medalist, having won relay gold in Sydney at the age of 33. Eight years later, at 41, Torres won three silver medals in Beijing, including placing second in the 50 free by .01, which wouldve made her the oldest gold medalist by six years if she had pulled out the win.

Incredibly, with Torres missing that victory by a mere hundredth, the oldest woman to win gold individually isInge de Bruijn, who was 11 years younger than Torres was in Beijing at the Athens Olympics in 2004 when she won the 50 free. GermanysUrsula Happe is the only other woman to win individual gold after the age of 30, while Phelps andDuke Kahanamoku join Ervin as the other two men to do so.

Data Notes:

Data Notes:

Data Notes:

Data Notes:

Excerpt from:

The Oldest Olympic Champions In Swimming History - SwimSwam

Posted in History | Comments Off on The Oldest Olympic Champions In Swimming History – SwimSwam

Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic … – MD Magazine

Posted: at 7:48 pm

Javed Butler, MD, MPH, MBA

Credit: Boehringer Ingelheim

A post hoc analysis of the phase 3 EMPEROR-Preserved trial suggests empagliflozin treatment in patients with heart failure with preserved ejection fraction (HFpEF) should be independent of diuretic therapy and could reduce the need for diuretics.1

The analysis showed empagliflozin was associated with comparable improvements in time to cardiovascular death (CV death) or hospitalization for heart failure (HHF), first and total HHF, rate of decline in estimated glomerular filtration rate (eGFR), and health status, regardless of baseline diuretic status or dose.

This is in line with findings from heart failure with reduced ejection fraction (HFrEF) patients in the DAPA-HF trial, where baseline diuretic therapy did not modify the benefit of dapagliflozin on these outcomes, wrote the investigative team, led by Javed Butler, MD, MPH, MBA, at the Baylor Scott and White Research Institute.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors primarily act through a diuretic mechanism and their benefit may be attenuated in patients already taking other diuretics. It is possible that the combined use of SGLT2 inhibitors with conventional diuretics may increase the risk of volume depletion events, acute kidney injury, and other adverse effects.2 Butler and colleagues indicated that the use of SGLT2 inhibitors could additionally impact the need for conventional diuretic therapy.

As a result, the post hoc analysis of the EMPEROR-Preserved trial aimed to assess the safety and efficacy of empagliflozin in relation to background diuretic therapy, as well as to study the association of empagliflozin with the use of conventional diuretics over time. The phase 3 trial was conducted from March 2017 - April 2021 and included individuals with New York Heart Association (NYHA) class II to IV heart failure and left ventricular ejection fraction 40%. A total of 5988 patients were enrolled and randomized to receive either empagliflozin (10 mg), or placebo.

Of the enrolled population, 5815 (97.1%) had data on baseline diuretic use and were included in the present analysis. Patients were categorized into the following subgroups according to baseline diuretic therapy: no diuretic use and furosemide-equivalent doses of 40 mg, 40 mg, and 40mg at baseline. The main clinical outcomes of interest were the composite endpoint of the first hospitalization for heart failure (HHF) or cardiovascular death (CV death), and its various components. Data were analyzed from November 2021 to August 2022.

Among the 5815 patients with known baseline diuretic use, 1179 (20.3%) were not taking diuretics, 1725 (29.7%) were taking 40mg, 1772 (30.5%) were taking 40 mg, and 1139 (19.6%) were taking 40 mg of furosemide-equivalent doses.

In the placebo arm, compared with the nondiuretic group, the analysis found the diuretic group had a higher risk of HHF or CV death (hazard ratio [HR], 1.81; 95% CI, 1.38 - 2.39; P <.001), total HHF (HR, 3.21; 95% CI, 2.15 - 4.80; P <.001), first HHF (HR, 2.75; 95% CI, 1.85 - 4.07; P <.001), and all-cause mortality (HR, 1.40; 95% CI, 1.06 - 1.85; P = .02). The results were similar after stratification by diuretic dose, with higher diuretic doses associated with a stepwise increase in these clinical outcomes.

Moreover, the analysis revealed empagliflozin treatment decreased the risk of HHF or CV death, regardless of background diuretic status (HR, 0.81; 95% CI, 0.70 - 0.93 for the diuretic group vs. HR, 0.72; 95% CI, 0.48 - 1.06 for the nondiuretic group; P for interaction = .58). There was no treatment by diuretic status interaction observed for CV death or all-cause death endpoints.

Compared with placebo, empagliflozin was associated with a slower rate of decline in the eGFR regardless of baseline diuretic use or dose. Additionally, the therapy was associated with improved Kansas City Cardiomyopathy Questionnaire 23 (KCCQ) clinical summary scores similarly in both the diuretic and nondiuretic groups at 12-week, 32-week, and 52-week follow-up. Results were consistent when patients were categorized by diuretic dose.

Among those taking diuretics at baseline, empagliflozin was associated with a significantly greater probability of de-escalation (HR, 1.15; 95% CI, 1.02 - 1.30), as well as a decreased likelihood of diuretic dose escalation (HR, 0.74; 95% CI, 0.65 - 0.84; P <.001). However, the analysis showed empagliflozin was associated with a higher incidence of volume depletion events in the diuretic group (7.5 vs. 5.6 events per 100 patient-years; HR, 1.34; 95% CI, 1.13 - 1.59).

The investigative team noted the important clinical implications of the analysis, suggesting SGLT2 inhibitors should not be withheld in patients not taking diuretics due to concerns of destabilizing the euvolemic status. Empagliflozin improved clinical outcomes without increasing volume depletion events in this population.

Butler and colleagues noted that at the time of SGLT2 initiation, most patients with HFpEF would not require a change in diuretic dose. However, they suggested that like every patient with heart failure, physicians should be ready to adjust the diuretic dose according to a patients individual needs.

Doing so will minimize the small risk of volume depletion when SGLT2 inhibitors and loop diuretics are combined, investigators wrote. Patient education, daily weights, and monitoring for volume depletion is advisable. In the longer term, as HF status improves in patients taking empagliflozin, the need for diuretics may be reduced.

References

See the article here:
Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine

Posted in Psoriasis | Comments Off on Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic … – MD Magazine

‘Tenacious’ Guyer softball team aims for more history at second-ever … – Denton Record Chronicle

Posted: at 7:48 pm

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Read the original post:

'Tenacious' Guyer softball team aims for more history at second-ever ... - Denton Record Chronicle

Posted in History | Comments Off on ‘Tenacious’ Guyer softball team aims for more history at second-ever … – Denton Record Chronicle

selectION reports results from SAD stage of si-544 Phase Ib trial – Clinical Trials Arena

Posted: at 7:48 pm

selectION has reported initial safety results from the single ascending dose (SAD) stage of its ongoing Phase Ib trial of si-544 for the treatment of atopic dermatitis.

si-544 is a selectivity-optimised peptide that blocks the Kv1.3 ion channel and helps in the activation and proliferation of TEM cells.

The placebo-controlled, double-blind, multi-centre study is designed to assess the tolerability, safety, and efficacy signals of the drug candidate in patients with mild to severe atopic dermatitis.

No safety signals or dose limiting toxicities have been observed during the studys first stage.

selectION chief scientific officer and co-founder Andreas Klostermann said: The ion channel Kv1.3 controls the activation and proliferation of auto-reactive effector memory T-cells and has been regarded a key target in T-cell autoimmunity for decades.

So far, it has not been possible to block this ion channel with sufficient selectivity.

The initial analysis of safety and tolerability data from 20 patients confirms that si-544 can be safely administered at dose levels sufficient to achieve virtually full Kv1.3 target engagement.

Based on the initial results, selectION now progresses the multiple ascending dose (MAD) stage of the Phase Ib trial.

Patients in this study will be treated with si-544 for a period of one month and thereafter monitored for three months.

selectION chairman and CEO Antonius Schuh said: The data provide initial clinical validation that we can safely and selectively target autoimmune disease associated chronically activated effector memory T-cells.

We will continue our path to deliver a potent and immune-selective therapy which maintains a patients general immunocompetency, and we believe that si-544 has the potential to significantly improve safety and outcomes for patients suffering from a wide range of autoimmune diseases, including atopic dermatitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, and many others.

See the original post here:
selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena

Posted in Psoriasis | Comments Off on selectION reports results from SAD stage of si-544 Phase Ib trial – Clinical Trials Arena